SEC Form 4 · accession 0001225208-19-004209
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lidia Fonseca
Officer — Executive Vice President
Period of report
Feb 28, 2019
Accepted (ET)
Mar 1, 2019 · 7:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | A | 47,510 | $0.00 | A | 47,510 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF2 | $43.35 | Feb 28, 2019 | A | 48,736 | A | Feb 28, 2024 | Feb 28, 2024 | Common Stock | 48,736 | 48,736 | D |
| Stock Appreciation RightsF3 | $43.35 | Feb 28, 2019 | A | 41,071 | A | Feb 28, 2026 | Feb 28, 2026 | Common Stock | 41,071 | 41,071 | D |
Explanation of responses
- F1The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.
- F2The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F3The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.